Josh Jennings
Stock Analyst at Morgan Stanley
(2.55)
# 2,058
Out of 5,182 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $18.93 | +179.98% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $182.87 | +64.05% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $5.16 | +287.60% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $16.56 | +280.43% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.60 | +1,066.67% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $82.28 | -51.39% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $18.93
Upside: +179.98%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $182.87
Upside: +64.05%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $5.16
Upside: +287.60%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $16.56
Upside: +280.43%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.60
Upside: +1,066.67%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $82.28
Upside: -51.39%